Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Mar 6;11:1362693. doi: 10.3389/fvets.2024.1362693

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2024 Garcia, Taborda, Reis, de Paula and Cassali.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Immunostaining to evaluate the molecular subtype of carcinomas in mixed tumours of the canine mammary gland. Shown here is a carcinoma in a mixed tumour without lymph node metastasis. (A) Strong nuclear immunostaining for oestrogen receptor in approximately 25% of neoplastic cells. Diaminobenzidine chromogen, haematoxylin counterstaining. (B) Strong nuclear immunostaining for progesterone receptor (brown areas) in more than 75% of neoplastic cells. Diaminobenzidine chromogen, haematoxylin counterstaining. (C) Strong cytoplasmic immunostaining for cyclooxygenase-2 in approximately 60% of neoplastic cells. Diaminobenzidine chromogen, haematoxylin counterstaining. (D) Strong nuclear immunostaining for Ki67 in approximately 10% of neoplastic cells. Diaminobenzidine chromogen, haematoxylin counterstaining. The scale bar is 50 μm.